
REGENXBIO (RGNX) Stock Forecast & Price Target
REGENXBIO (RGNX) Analyst Ratings
Bulls say
Regenxbio is likely to continue to face high financing needs in the near future, potentially leading to share dilution for shareholders, but this is a common issue faced by many biotech companies. Additionally, the company operates in a competitive market with other gene therapy treatments already on the market. However, the company's partnerships with other biotech companies could potentially mitigate risks and costs, but external factors such as pipeline failures or management missteps could still impact the company's stock performance.
Bears say
Regenxbio is facing regulatory setbacks and competition in the gene therapy market, with a negative FDA response to their treatment RGX-121 and challenges in finding appropriate pricing models and managing partnerships. Positive 18-month data for their treatment RGX-202 has been reported, but its estimated market value of $1.64B may not be enough to offset any potential losses from other programs or partnerships. Share dilution is also a concern, which may further impact the company's financials.
This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.
REGENXBIO (RGNX) Analyst Forecast & Price Prediction
Start investing in REGENXBIO (RGNX)
Order type
Buy in
Order amount
Est. shares
0 shares